HCC updates from ILCA and ESMO congressess 2022

Episode 1 October 06, 2022 00:30:22
HCC updates from ILCA and ESMO congressess 2022
COR2ED Medical Education
HCC updates from ILCA and ESMO congressess 2022

Oct 06 2022 | 00:30:22

/

Show Notes

COR2ED Medical Education: In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

Other Episodes

Episode 1

May 03, 2022 00:22:30
Episode Cover

Immune tolerance induction in the era of emicizumab

COR2ED Medical Education: In this podcast, two haematology experts discuss their views on the use of immune tolerance induction (ITI) in haemophilia. Prof. Jan...

Listen

Episode 3

October 21, 2021 00:17:57
Episode Cover

Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Future Developments - Ep 3

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité...

Listen

Episode 14

June 20, 2023 00:23:12
Episode Cover

Breast Cancer : Oral SERDs in ER+ breast cancer. Episode 1 - efficacy and safety and treatment landscape

COR2ED Medical Education: In this podcast, the experts give an overview of  the EMERALD trial  and present elacestrant as the first, and currently only,...

Listen